56,904 Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Bought by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 56,904 shares of the biopharmaceutical company’s stock, valued at approximately $94,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after buying an additional 3,688,796 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 11,658 shares in the last quarter. Capital Advisors Wealth Management LLC raised its holdings in shares of Esperion Therapeutics by 22.9% in the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 5,000 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in shares of Esperion Therapeutics in the second quarter worth $132,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Analyst Upgrades and Downgrades

ESPR has been the topic of several recent research reports. Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, December 3rd.

Esperion Therapeutics Trading Up 4.2 %

Esperion Therapeutics stock opened at $3.48 on Monday. The company has a market capitalization of $685.68 million, a price-to-earnings ratio of -5.44 and a beta of 1.01. The stock’s 50 day moving average is $2.29 and its 200-day moving average is $2.20. Esperion Therapeutics, Inc. has a 12 month low of $1.35 and a 12 month high of $3.81.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.